A late-February snapshot of the United States market shows cross-currents: equity benchmarks face a rough month amid AI-led volatility and an approaching U.S. jobs report, while some strategists are dialing back enthusiasm for U.S. stocks. In commodities, gold is supported by risk and geopolitics, and copper-related trade flows remain in focus after a surge in December imports. Meanwhile, market plumbing and access themes also surface—from a new OTCQX listing to legal battles around prediction markets—alongside long-range industry forecasts for multiple U.S. materials and chemicals segments.

1. US equity markets were being shaped by AI-related uncertainty heading into a week with U.S. jobs data as a key focal point. 2. UBS downgraded its weighting on U.S. equities to neutral. 3. CNN reported that the Nasdaq and S&P 500 were set for their worst month since March and discussed how to navigate the shift. 4. Some market commentary linked U.S. stock weakness to Nvidia’s decline even as broader participation was mixed and oil prices were volatile. 5. Reuters highlighted that U.S. payrolls data were a central question for markets, framing whether a hot streak was real or a head fake. 6. Gold prices were steady as markets awaited the outcome of U.S.-Iran nuclear talks. 7. Gold was also heading for a seventh straight monthly gain on safe-haven demand, according to Reuters. 8. Reuters reported that U.S. copper dynamics remained in focus after a December import surge. 9. RUA GOLD began trading on the OTCQX Best Market in the United States, according to Investing News Network. 10. Reuters reported that prediction market operator Kalshi hired prominent appellate lawyer Neal Katyal in cases involving prediction markets. 11. Cushman & Wakefield said the Americas data center market has shifted to “managed growth.” 12. IndexBox forecast the U.S. heterocyclic compounds market would reach 355K tons and $14.1 billion by 2035. 13. IndexBox projected the U.S. non-cellular plastics market would reach 1.6 million tons and $9.6 billion by 2035. 14. IndexBox projected steady 2.6% CAGR growth for the U.S. polycarboxylic acids market through 2035.